三生製藥(01530.HK)溢價25%發行CB 並回購1.58億歐元舊有CB
三生製藥(01530.HK)公布,購回本金總額1.58億歐元之現有零票息可換股債券,完成後,發行在外的現有可換股債券本金額將為1.37億歐元,以換股價每股14.28元計算,可悉數轉換成8,608.27萬股股份。
公司並公布,發行本金總額3.2億歐元的新債券,初步轉換價每股13.175元,較股份昨日收市價10.54元溢價25%。根據相關價格,債券可悉數轉換成2.12億股,佔公司擴大後股本7.71%。發行所得淨額料為3.15億歐元,將用作同步購回或現有可換股債券持有人於行使認沽期權後贖回現有可換股債券而所需的付款,及研發、購買營運設施,及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.